Lig­and Phar­ma part­ner wins Chi­nese ap­proval for an­ti-PD-1; Brick­ell re­ceives ex­clu­sive rights to DYRK1A in­hibitor

Cal­i­for­nia bio­phar­ma com­pa­ny Lig­and Phar­ma­ceu­ti­cals an­nounced to­day that part­ner Glo­ria Bio­sciences has re­ceived a new ap­proval from Chi­na’s Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion.

This ap­proval is for the an­ti-PD-1 an­ti­body zim­bere­limab for treat­ing re­cur­rent or re­frac­to­ry clas­si­cal Hodgkin’s lym­phoma.

Read the source article at endpts.com
2021-09-01 15:27:41